Рак желудка – современные тенденции в диагностике и лечении на примере опыта российских клиник по данным исследования REGATE

1. Parkin D, Bray F, Ferlay J, Pisani D. Global cancer statistics. Cancer J Clin 2005; 55: 74–108.
2. Ter-Ovanesov M, Bang Y et al. REGATE: What happens to gastric cancer treatment in the real world? Ann Onc 2006; 17 (Suppl. 6): 013.
3. Bang YJ, Ter-Ovanesov M, Wu CW et al. REGATE: Planned and actual strategies of gastric cancer treatment. ASCO GI 2007; abs 60.
4. Solcia E, Fiocca R, Luinetti O et al. Intestinal and diffuse gastric cancers arise in a different background of Helicobacter Pylori gastritis through different gene involvement. Am J Surg Pathol 1996; 20 (Suppl. 1): S8–22.
5. Nishi M, Ichikawa H, Nakajima T et al. Gastric cancer. Springer-Verlag, 1993.
6. Japanese Classification of Gastric Cancer – 2nd English Edition. Japanese Gastric Cancer Association. Gastric Cancer 1998; 1: 10–24.
7. UICC & AJCC Cancer Staging Manual, 6th ed. Lippincott-Raven Publs, 2002.
8. Aiko T, Sasako M. For General Rules Committee of the Japanese Gastric Cancer Association. The new Japanese classification of Gastric Carcinoma: points to be revised. Gastric Cancer 1998; 1: 25–30.
9. Hermanek P. The second English edition of the Japanese Classification of Gastric Carcinoma. A Western commentary. Gastric Cancer 1999; 2: 79–82.
10. Sasako M, Aiko T. Reply to Professor Hermanek’s comments on the new Japanese classification of gastric carcinoma. Gastric Cancer 1999; 2: 83–5.
11. Maruyama K, Gunvin P, Kinoshita T et al. Lymph node metastasis of gastric cancer: general patterns in 1931 patients. Ann Surg 1989; 210: 596–602.
12. Takagane A, Terishima M, Abe K et al. Clinicopathological studies on skip metastasis of lymph nodes in patients with respectable gastric cancer. J Iwate Med Associat 1998; 50: 331–6.
13. Aiko T, Sasako M. For General Rules Committee of the Japanese Gastric Cancer Association. The new Japanese classification of Gastric Carcinoma: points to be revised. Gastric Cancer 1998; 1: 25–30.
14. Тер-Ованесов М.Д. Факторы прогноза хирургического лечения рака проксимального отдела желудка. Дис. ... д-ра мед. наук. М., 2007.
15. Hartgrink HH, van de Velde CJ, Putter H et al. Neo-adjuvant chemotherapy for operable gastric cancer: long term results of the Dutch randomized FAMTX trial. Eur J Surg Oncol 2004; 30: 643–9.
16. David Cunningham, William H Allum, Sally P. Stenning et al. for the MAGIC Trial: Perioperative Chemotherapy versus Surgery Alone for Resectable Gastroesophageal Cancer NEJM, 2006; 355: 11–20.
17. Macdonald JS, Smalley SR, Benedetti J et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001; 345: 725–30.
18. Sano T, Sasako M. For the Gastric Cancer Surgical Study Group of  the Japan Clinical Oncology Group (JCOG). Randomised controlled trial to evaluate para-aortic lymphadenectomy for gastric cancer (JCOG 9501). IVth International Gastric Cancer Congress, Abstructs, S 45: p. 663.
19. Sasako M. Extent of Lymphadenectomy in gastric Cancer:  Have we Finally come to a Consensus? Gastrointestinal Cancer Symposium: multidisciplinary approaches to the prevention, diagnosis and therapy of GI Cancer, 2007; 39–41.
20.  Ross P, Nicolson M, Cunningham D et al. Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J Clin Oncol 2002; 20: 1996–2004.